Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insight on Key Data From SGO 2021 Informing Treatment for Endometrial and Ovarian Cancer

The 2021 SGO Virtual Annual Meeting, 19-25 March 2021, in Seattle, Washington, USA; The 2021 ASCO Annual Meeting, 4-8 June 2021, in Chicago, Illinois, USA; The 2021 IGCS Meeting, 30 August - 2 September, in Rome, Italy; The ESMO 2021 Annual Congress, 17-21 September 2021, in Paris, France; The 2021 ESGO Conference, 23-26 October 2021, in Prague, Czech Republic

In this podcast episode, listen to Ursula Matulonis, MD, and Jubilee Brown, MD, discuss new data for gynecological cancers presented at the virtual SGO 2021 meeting, including immunotherapy-based combinations for endometrial cancer and PARP inhibitors for BRCA-mutated ovarian cancers.

This podcast is intended for clinicians practicing medicine outside of the United States.

Jubilee Brown, MD
Ursula Matulonis, MD
Released: April 7, 2021

In this episode, Jubilee Brown, MD, and Ursula Matulonis, MD, provide expert perspectives on new data from SGO 2021 presented for endometrial and ovarian cancer including:

  • Results from KEYNOTE-775, a phase III trial of lenvatinib plus pembrolizumab in advanced endometrial cancer
  • Results from the confirmatory phase III ARIEL4 evaluating rucaparib vs chemotherapy in BRCA-mutated relapsed ovarian cancer
  • 5-year follow-up from SOLO-1 trial of olaparib vs placebo in BRCA-mutated, newly diagnosed ovarian cancer
  • Long-term follow-up results from the phase III ENGOT-OV16/NOVA trial of niraparib in patients with recurrent ovarian cancer
  • OPAL: a phase II study evaluating dostarlimab, bevacizumab, and niraparib in platinum-resistant ovarian cancer

Presenters:

Jubilee Brown, MD
Professor and Director of Gynecologic Oncology
Levine Cancer Institute
Atrium Health
Charlotte, North Carolina

Ursula Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Acknowledgements

This educational activity is supported by an educational grant from
GlaxoSmithKline

Related Content

Drs Ritu Salani and Eva Y. Pan discuss optimal approaches to current treatment of patients with gynecologic cancers in this module from Clinical Care Options (CCO)

Eva Y. Pan, PharmD, BCOP Ritu Salani, MD, MBA Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: May 13, 2022 Expired: May 12, 2023

Podcast with Dr. Nelson F. Sanchez on caring for transgender individuals, from the healthcare disparities they face to how HCPs can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD Released: May 13, 2022

Drs Ritu Salani and Eva Y. Pan discuss optimal approaches to current treatment of patients with gynecologic cancers in this module from Clinical Care Options (CCO)

Eva Y. Pan, PharmD, BCOP Ritu Salani, MD, MBA Released: May 13, 2022

Commentary on immunotherapy in endometrial cancer with a focus on older patients, from Clinical Care Options (CCO)

Domenica Lorusso, MD, PhD Released: April 29, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings